Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancer

Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancer - Early secondary treatment with nibolumab for NSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030457

Enrollment

Registered

2018-01-01

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Nivolumab 3mg/kg every 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically diagnosed non-small-cell Non-small-cell lung cancer of stage IIIB or IV Reccurence of operation or concurrent chemoradiotherapy Patients without driver gene mutation (i.e. EGFR/ALK/RET/ROS1) Expression of PD-L1 in adenocarcinoma are 0-49% Expression of PD-L1 in squamouscarcinoma are 1-49% Adequate organ function 3 months or longer expected survival Written informed consent Age over 20 years old ECOG PS 0-1 Measurable lesion

Exclusion criteria

Exclusion criteria: Active auto-immune disease An inappropriate case judged by doctor in charge

Design outcomes

Primary

Measure	Time frame
Disease control rate at 24 weeks after initiation of nivolumab therapy	—

Secondary

Measure	Time frame
Progression-free survival, Overall survival, Time to treatment failure, Response rate, Adverse events	—

Countries

Japan

Contacts

Public ContactYasuhiro Goto

Fujita Health University School Medicine department of pulmonary

gotoyasu510@hotmail.com0562-93-9241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026